Fluvoxamine, melatonin and COVID-19. | Psychopharmacology (Berl);238(2): 611, 2021 02. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Fluvoxamine, melatonin and COVID-19.

Anderson, George M.

Anderson GM; Child Study Center and the Department of Laboratory Medicine, Yale University School of Medicine, 230 S. Frontage Rd., New Haven, CT, 06525, USA. george.anderson@yale.edu.

Psychopharmacology (Berl) ; 238(2): 611, 2021 02.

Article in English | MEDLINE | ID: covidwho-1002070

Subject(s)

COVID-19; Clinical Deterioration; Melatonin; Fluvoxamine; Humans; Outpatients; SARS-CoV-2

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Clinical Deterioration / COVID-19 / Melatonin Type of study: Prognostic study Limits: Humans Language: English Journal: Psychopharmacology (Berl) Year: 2021 Document Type: Article Affiliation country: S00213-020-05753-z

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Clinical Deterioration / COVID-19 / Melatonin Type of study: Prognostic study Limits: Humans Language: English Journal: Psychopharmacology (Berl) Year: 2021 Document Type: Article Affiliation country: S00213-020-05753-z